Tag: GEJ

Lilly’s Cyramza fails to improve overall survival in gastric cancer

by Selina McKee | Dec 11, 2017 | News | 0

Eli Lilly’s Cyramza has hit its primary goal in a late-stage study showing extended progression-free survival in patients with gastric cancer, but the drug failed to improve overall survival, a secondary endpoint.

Avelumab fails to improve survival in gastric cancer

by Selina McKee | Nov 29, 2017 | News | 0

Merck and Pfizer have revealed that a Phase III trial assessing avelumab in patients with gastric cancer after two prior therapeutic regimens failed to hit its primary target of showing an improvement in survival.